Related references
Note: Only part of the references are listed.Post marketing surveillance (PMS) in Japan for soft tissue sarcoma (STS) patients treated with pazopanib
A. Kawai et al.
EUROPEAN JOURNAL OF CANCER (2015)
Hypertension (HTN) as a potential biomarker of efficacy in pazopanib-treated patients with advanced non-adipocytic soft tissue sarcoma. A retrospective study based on European Organisation for Research and Treatment of Cancer (EORTC) 62043 and 62072 trials
F. Duffaud et al.
EUROPEAN JOURNAL OF CANCER (2015)
Differences in the responses to pazopanib and the prognoses of soft tissue sarcomas by their histological eligibility for the PALETTE study
Kenji Nakano et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2015)
Long-term responders and survivors on pazopanib for advanced soft tissue sarcomas: subanalysis of two European Organisation for Research and Treatment of Cancer (EORTC) clinical trials 62043 and 62072
B. Kasper et al.
ANNALS OF ONCOLOGY (2014)
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial
Ian Judson et al.
LANCET ONCOLOGY (2014)
Pneumothorax as adverse event in patients with lung metastases of soft tissue sarcoma treated with pazopanib: a single reference centre case series
Arie J. Verschoor et al.
CLINICAL SARCOMA RESEARCH (2014)
Cediranib for Metastatic Alveolar Soft Part Sarcoma
Shivaani Kummar et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Cytokine and angiogenic factors associated with efficacy and toxicity of pazopanib in advanced soft-tissue sarcoma: an EORTC-STBSG study
S. Sleijfer et al.
BRITISH JOURNAL OF CANCER (2012)
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
Winette T. A. van der Graaf et al.
LANCET (2012)
Pazopanib: Clinical development of a potent anti-angiogenic drug
Fabio A. B. Schutz et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2011)
Multicenter Phase II Trial of Sunitinib in the Treatment of Nongastrointestinal Stromal Tumor Sarcomas
Suzanne George et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Pazopanib, a Multikinase Angiogenesis Inhibitor, in Patients With Relapsed or Refractory Advanced Soft Tissue Sarcoma: A Phase II Study From the European Organisation for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC Study 62043)
Stefan Sleijfer et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Medical progress: Soft-tissue sarcomas in adults
MA Clark et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Prognostic factors for patients with localized soft-tissue sarcoma treated with conservation surgery and radiation therapy - An analysis of 1225 patients
GK Zagars et al.
CANCER (2003)
Share Paper
